Last July, Sen. Claire McCaskill (D-Mo.) asked several drug makers and wholesalers to provide various forms of information about the steps they have taken to mitigate the opioid epidemic. But one company, Teva Pharmaceuticals (TEVA), is “stonewalling,” as far as she is concerned.
Instead of turning over documents about monitoring suspicious orders — a key focus of her investigation — Teva responded with two brief letters describing those efforts. And in a second letter sent in October, Teva attorneys maintained the drug maker has been willing to discuss, “at a general level,” the information requested, but acknowledged the company “declined to produce the documents.”
So, now, McCaskill is going public with a veiled threat.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
